Zymeworks contracts ProBioGen for bispecific GlymaxX antibody cell line development to enhance ADCC potency of antibody

Company’s second office in the region will strengthen customer relations and help develop new business among emerging and established Japanese companies

DDNews conducts a Q&A with Paula Soteropoulos of Akcea Therapeutics on transforming the landscape of cardiometabolic lipid disorders

Peregrine Pharmaceuticals Inc. has provided a clinical development update for bavituximab, the company’s investigational phosphatidylserine-targeting immunotherapy.

Baxalta to be acquired by Shire as its collaboration with Coherus on CHS-0214 biosimilar meets primary efficacy endpoint in Phase 3 rheumatoid arthritis clinical study

Alliance to focus on development and commercialization of regenerative medicine products for stroke and other potential indications using new regulatory framework in Japan

Researchers have created a computer program that they believe will open a challenging field in synthetic biology to the entire world.

Focus is children and young adults with treatment-resistant epilepsy

High statistical significance in prevention of recurrence of posterior uveitis (p less than 0.00000001)

• FDA designation reinforces potential for BI 1482694 to become a new treatment option for patients with EGFR mutation-positive lung cancer with a T790M mutation • Phase 1/2 data presented at ESMO Asia 2015 Congress showed 62 percent objective responses in patients treated with BI 1482694, including 32 patients (46 percent) with confirmed tumor response • New global Phase 2 trial ELUXA 1 study enrolling patients

Phase 2 protocol for a transplantation indication cleared for patient enrollment

First-in-man study demonstrates highly successful performance of the LuxCath system to optically assess tissue contact before and during ablation